2024-512463-31-00招募中1 期
Phase I trial with 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours
Vaestra Goetalandsregionen1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2024年10月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Andreas Hallqvist
Scientific
Vaestra Goetalandsregionen
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3)2024-518325-15-00Novartis Pharma AG99
招募中
2 期
Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations2024-510970-26-00Asociacion Grupo Tratamiento De Tumores Digestivos40
招募中
2 期
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseNCT07272499Ruijin Hospital25
招募中
2 期
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)Cancer2023-508422-95-00Synthorx Inc.31
招募中
3 期
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85